Sio Gene Therapies Inc represents values of innovation, integrity, and patient-centricity. With a strong corporate philosophy focused on improving the lives of patients, Sio Gene Therapies Inc is dedicated to developing transformative gene therapies for various genetic and neurological disorders. Through cutting-edge scientific research and collaborative partnerships, the company aims to bring hope and effective treatments to those in need. Sio Gene Therapies Inc's commitment to delivering life-changing therapies aligns with its vision to redefine medical possibilities and provide a brighter future for patients worldwide.

Sio Gene Therapies Inc is primarily present in the United States.

Sio Gene Therapies Inc has achieved several significant milestones. Firstly, the company successfully completed a phase 1/2 clinical trial for AXO-Lenti-PD, a gene therapy candidate for Parkinson's disease. This breakthrough demonstrated the therapy's safety and potential efficacy. Additionally, Sio Gene Therapies received FDA Fast Track designation for AXO-AAV-GM1, a gene therapy for GM1 gangliosidosis, a rare neurodegenerative disorder. The company also entered a collaboration with Axovant Gene Therapies to develop and commercialize gene therapies for different CNS diseases. Moreover, Sio Gene Therapies received Orphan Drug Designation for AXO-AAV-GM2, a gene therapy targeting Tay-Sachs and Sandhoff diseases. These achievements highlight the company's dedication to revolutionizing the treatment of debilitating genetic diseases.

Sio Gene Therapies Inc, formerly known as Axovant Gene Therapies, is a biotechnology company focused on developing and commercializing gene therapies for neurological disorders. Founded in 2014, Sio Gene Therapies has its headquarters in New York City. The company aims to provide innovative treatments for various genetic and neurodegenerative diseases, including Parkinson's disease, Tay-Sachs disease, and ALS. With a commitment to advancing gene therapy research, Sio Gene Therapies collaborates with leading academic institutions and industry partners. By leveraging cutting-edge gene therapy technologies, the company strives to improve the lives of patients worldwide.

The main competitors of Sio Gene Therapies Inc in the market include companies such as Novartis AG, Pfizer Inc., and Spark Therapeutics Inc. These companies also specialize in the development and commercialization of gene therapies, making them direct competitors of Sio Gene Therapies Inc.

Sio Gene Therapies Inc is primarily active in the biotechnology and pharmaceutical industries. As a leading gene therapy company, Sio Gene Therapies Inc focuses on developing and delivering transformative genetic medicines for patients with neurological diseases. With their cutting-edge technology and innovative research, Sio Gene Therapies Inc is dedicated to addressing unmet medical needs and improving the lives of individuals affected by genetic disorders. By leveraging their expertise in gene therapy, Sio Gene Therapies Inc aims to revolutionize the treatment landscape and create long-lasting solutions for patients in need.

The business model of Sio Gene Therapies Inc is focused on developing and commercializing gene therapies to treat genetic and neurodegenerative diseases. Sio Gene Therapies aims to leverage its expertise in genetic medicine and gene delivery platforms to deliver transformative therapies. The company's approach involves using gene therapy to address underlying genetic causes, aiming for long-lasting and potentially curative treatments. By developing innovative gene therapies, Sio Gene Therapies aims to improve patient outcomes and address significant unmet medical needs in various therapeutic areas.

Sio Gene Therapies hissesinin F/K oranı -0,54.

Sio Gene Therapies KUV 2,15 dir.

Sio Gene Therapies için AlleAktien Kalite Skoru 1/10'dur.

beklenen Sio Gene Therapies cirosu 16,27 Milyon. USD dir.

beklenen Sio Gene Therapies karı -64,90 Milyon. USD olarak gerçekleşmiştir.

Sio Gene Therapies is a biotechnology company focused on the development and commercialization of gene therapy products for rare and neurological diseases. The company is headquartered in New York and is listed on NASDAQ under the ticker symbol "SIOX". Sio Gene Therapies' business model is based on the discovery and development of novel gene therapies for the treatment of genetic diseases. The company has unique expertise in the development of adeno-associated virus (AAV)-based gene therapies and collaborates closely with leading scientists and academic institutions to develop new technologies and therapies. Sio Gene Therapies has a pipeline of therapeutics in various stages of clinical development. The company's products are designed to treat the genetic mutations that cause specific diseases. These gene therapies can directly repair the defective gene or introduce a healthy gene into the body to replace the faulty function of the corresponding protein. The different divisions of Sio Gene Therapies include the clinical development of gene therapies for rare diseases and neurological diseases. The company has a range of gene therapies in development aimed at treating diseases such as Huntington's disease, spinal muscular atrophy, Friedreich's ataxia, and Angelman syndrome. The flagship product of Sio Gene Therapies is AXO-Lenti-PD, a gene therapy for the treatment of Parkinson's disease. The company developed this therapy in collaboration with the College of Medicine at the University of Florida. It is a Phase 2 clinical trial aimed at alleviating the symptoms of Parkinson's in patients by directly repairing the Parkinson's-causing gene. Sio Gene Therapies has also entered into a strategic partnership with Asklepios BioPharmaceuticals, Inc. to expand access to AAV-based gene therapies. This joint venture aims to accelerate the clinical development and manufacturing of gene therapies and further enhance expertise in gene therapy development. Overall, Sio Gene Therapies' business model is based on the discovery and development of novel gene therapy products for the treatment of genetic diseases. The company focuses on the clinical development of gene therapies for rare and neurological diseases and has a range of products in various stages of clinical development. With AXO-Lenti-PD, the company has already achieved an important milestone in gene therapy development. Sio Gene Therapies is a biotechnology company specializing in the development and commercialization of gene therapy products for rare and neurological diseases. Its headquarters are in New York and it is listed on NASDAQ under the symbol "SIOX". The company's business model is centered around discovering and developing innovative gene therapies to treat genetic disorders. Sio Gene Therapies has expertise in developing adeno-associated virus (AAV)-based gene therapies and collaborates with leading scientists and academic institutions to create new technologies and therapies. The company has a pipeline of therapeutics in various stages of clinical development. These products aim to treat specific diseases by repairing defective genes or introducing healthy genes into the body to replace dysfunctional proteins. Sio Gene Therapies focuses on the clinical development of gene therapies for rare and neurological diseases and has several therapies in development for conditions such as Huntington's disease, spinal muscular atrophy, Friedreich's ataxia, and Angelman syndrome. Its flagship product, AXO-Lenti-PD, is a gene therapy for Parkinson's disease developed in collaboration with the College of Medicine at the University of Florida. This therapy is currently in Phase 2 clinical trials and aims to alleviate Parkinson's symptoms by directly repairing the disease-causing gene. Sio Gene Therapies has also formed a strategic partnership with Asklepios BioPharmaceuticals, Inc. to expand access to AAV-based gene therapies and enhance expertise in gene therapy development and manufacturing. In summary, Sio Gene Therapies' business model is based on discovering and developing innovative gene therapy products for genetic diseases. The company focuses on the clinical development of gene therapies for rare and neurological diseases and has achieved a significant milestone with AXO-Lenti-PD.

Sio Gene Therapies, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

Sio Gene Therapies için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Sio Gene Therapies şirketinin ISIN kodu US8293991043’dir.

Sio Gene Therapies 'nin WKN'si A2QHKW 'dir.

Sio Gene Therapies için Ticker SIOX’dir.

Son 12 ay içerisinde Sio Gene Therapies, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Sio Gene Therapies, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

Sio Gene Therapies şirketinin mevcut temettü verimi .

Sio Gene Therapies dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Sio Gene Therapies, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Sio Gene Therapies, 'Sağlık' sektörüne atanmıştır.

Son Sio Gene Therapies tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 17.07.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 17.07.2024 olarak gerçekleşti.

2023 yılında Sio Gene Therapies tarafından 0 USD olarak temettüler dağıtıldı.

Sio Gene Therapies hisselerinin temettüleri USD olarak dağıtılır.